Aquestive Therapeutics, Inc. (AQST) News
Track canonical SquawkNews coverage tagged to AQST, Aquestive Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 11 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Aquestive Therapeutics posts investor presentation; NDA resubmission for Anaphylm, $98.5M cash
Aquestive Therapeutics disclosed an investor presentation detailing an NDA resubmission for Anaphylm and its cash runway of $98.5 million.Key Highlights:Original SEC Filing: Aquestive Therapeutics, Inc. [ AQST ] - 8-K -
REGULATION | Sep 25, 2026, 12:05 PM UTC
M
Aquestive Therapeutics resubmits NDA for Anaphylm
The company said it resubmitted its New Drug Application for Anaphylm after supportive human factors and pharmacokinetic study results.
EQUITY | Sep 17, 2026, 11:14 AM UTC
L
AQST - Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
AQST - Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
REGULATION | Sep 17, 2026, 11:00 AM UTC
L
AQST: Anaphylm's rapid, user-friendly delivery and strong clinical profile position it for major market impact
Anaphylm, a sublingual film for severe allergic reactions, is poised for FDA resubmission with improved packaging and strong clinical data showing rapid onset and robust efficacy. The company is launch-ready with secured
REGULATION | Sep 09, 2026, 08:11 PM UTC
L
Aquestive Therapeutics to participate in upcoming September investor conferences
Aquestive Therapeutics said it will participate in upcoming September investor conferences.
EQUITY | Sep 01, 2026, 11:08 AM UTC
L
AQST - Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
AQST - Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
EQUITY | Sep 01, 2026, 11:00 AM UTC
L
Aquestive Therapeutics Reports Earnings Miss
Aquestive Therapeutics reports EPS miss by 8c, revenue beat
EARNINGS | Aug 11, 2026, 08:03 PM UTC
L
Aquestive Therapeutics Q2 EPS $(0.18) Misses $(0.12) Estimate, Sales $13.819M Beat $11.418M Estimate
Aquestive Therapeutics Q2 EPS $(0.18) Misses $(0.12) Estimate, Sales $13.819M Beat $11.418M Estimate
EARNINGS | Aug 11, 2026, 08:01 PM UTC
L
AQST - Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
AQST - Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Aug 11, 2026, 08:01 PM UTC
L
Aquestive Therapeutics Affirms FY2026 Sales Guidance of $46.000M-$50.000M vs $50.584M Est
Aquestive Therapeutics (NASDAQ: AQST ) affirms FY2026 sales outlook from $46.000 million-$50.000 million to $46.000 million-$50.000 million vs $50.584 million estimate.
EARNINGS | Aug 11, 2026, 08:01 PM UTC
L
AQST - Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conferenc
AQST - Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
EARNINGS | Jul 29, 2026, 11:00 AM UTC